Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic

OBJECTIVES: Guidelines cautioned prescribing of tumour necrosis factor inhibitors (TNFi) to patients with rheumatoid arthritis and interstitial lung disease (RA-ILD) after reports of new or worsening of ILD. Less is known about outcomes among patients with RA-ILD who receive rituximab (RTX). This st...

Descripción completa

Detalles Bibliográficos
Autores principales: Druce, Katie L, Iqbal, Kundan, Watson, Kath D, Symmons, Deborah P M, Hyrich, Kimme L, Kelly, Clive
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604605/
https://www.ncbi.nlm.nih.gov/pubmed/28955489
http://dx.doi.org/10.1136/rmdopen-2017-000473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604605/
https://www.ncbi.nlm.nih.gov/pubmed/28955489
http://dx.doi.org/10.1136/rmdopen-2017-000473

Ejemplares similares